Trial Outcomes & Findings for A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (NCT NCT02994927)

NCT ID: NCT02994927

Last Updated: 2025-03-24

Results Overview

Disease remission at Week 26 was defined as: * Achieving a BVAS of 0 as determined by the Adjudication Committee; * No administration of glucocorticoids given for ANCA-associated vasculitis within 4 weeks prior to Week 26; * No BVAS \>0 during the 4 weeks prior to Week 26 (if collected for an unscheduled assessment).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

331 participants

Primary outcome timeframe

Week 26

Results posted on

2025-03-24

Participant Flow

A total of 143 study centers randomized at least 1 subject. The target enrollment was 300 subjects.

Screening details: Of 386 subjects screened, 331 were enrolled in the study and randomized to treatment. Reasons for subjects failing screening included not meeting inclusion/exclusion criteria, withdrawal by subject, adverse event (AE) and other.

Participant milestones

Participant milestones
Measure
Prednisone Group
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone
Avacopan Group
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo
Overall Study
STARTED
165
166
Overall Study
COMPLETED
150
151
Overall Study
NOT COMPLETED
15
15

Reasons for withdrawal

Reasons for withdrawal
Measure
Prednisone Group
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone
Avacopan Group
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo
Overall Study
Withdrawal by parent/guardian
0
1
Overall Study
Did not meet eligibility criteria
0
1
Overall Study
Physician Decision
4
3
Overall Study
Death
4
2
Overall Study
Adverse Event
2
1
Overall Study
Withdrawal by Subject
3
6
Overall Study
Lost to Follow-up
2
1

Baseline Characteristics

Two subjects did not have a baseline BMI provided (one in each treatment group)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo
Total
n=330 Participants
Total of all reporting groups
Age, Customized
Adolescents (12-17 years)
1 Participants
n=164 Participants
2 Participants
n=166 Participants
3 Participants
n=330 Participants
Age, Customized
Adults (18-50 years)
28 Participants
n=164 Participants
30 Participants
n=166 Participants
58 Participants
n=330 Participants
Age, Customized
Adults (51-64 years)
61 Participants
n=164 Participants
48 Participants
n=166 Participants
109 Participants
n=330 Participants
Age, Customized
Adults (65-75 years)
52 Participants
n=164 Participants
62 Participants
n=166 Participants
114 Participants
n=330 Participants
Age, Customized
Adults (>75 years)
22 Participants
n=164 Participants
24 Participants
n=166 Participants
46 Participants
n=330 Participants
Sex: Female, Male
Female
76 Participants
n=164 Participants
68 Participants
n=166 Participants
144 Participants
n=330 Participants
Sex: Female, Male
Male
88 Participants
n=164 Participants
98 Participants
n=166 Participants
186 Participants
n=330 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=164 Participants
7 Participants
n=166 Participants
12 Participants
n=330 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
157 Participants
n=164 Participants
151 Participants
n=166 Participants
308 Participants
n=330 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants
n=164 Participants
8 Participants
n=166 Participants
10 Participants
n=330 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=164 Participants
0 Participants
n=166 Participants
0 Participants
n=330 Participants
Race (NIH/OMB)
Asian
15 Participants
n=164 Participants
17 Participants
n=166 Participants
32 Participants
n=330 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=164 Participants
0 Participants
n=166 Participants
0 Participants
n=330 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=164 Participants
3 Participants
n=166 Participants
5 Participants
n=330 Participants
Race (NIH/OMB)
White
140 Participants
n=164 Participants
138 Participants
n=166 Participants
278 Participants
n=330 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=164 Participants
0 Participants
n=166 Participants
1 Participants
n=330 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
n=164 Participants
8 Participants
n=166 Participants
14 Participants
n=330 Participants
Region of Enrollment
Australia
4 participants
n=164 Participants
10 participants
n=166 Participants
14 participants
n=330 Participants
Region of Enrollment
Austria
3 participants
n=164 Participants
3 participants
n=166 Participants
6 participants
n=330 Participants
Region of Enrollment
Belgium
4 participants
n=164 Participants
6 participants
n=166 Participants
10 participants
n=330 Participants
Region of Enrollment
Canada
5 participants
n=164 Participants
8 participants
n=166 Participants
13 participants
n=330 Participants
Region of Enrollment
Czechia
7 participants
n=164 Participants
2 participants
n=166 Participants
9 participants
n=330 Participants
Region of Enrollment
Denmark
10 participants
n=164 Participants
6 participants
n=166 Participants
16 participants
n=330 Participants
Region of Enrollment
France
18 participants
n=164 Participants
22 participants
n=166 Participants
40 participants
n=330 Participants
Region of Enrollment
Germany
32 participants
n=164 Participants
22 participants
n=166 Participants
54 participants
n=330 Participants
Region of Enrollment
Italy
2 participants
n=164 Participants
9 participants
n=166 Participants
11 participants
n=330 Participants
Region of Enrollment
Japan
10 participants
n=164 Participants
11 participants
n=166 Participants
21 participants
n=330 Participants
Region of Enrollment
Netherlands
5 participants
n=164 Participants
1 participants
n=166 Participants
6 participants
n=330 Participants
Region of Enrollment
New Zealand
2 participants
n=164 Participants
2 participants
n=166 Participants
4 participants
n=330 Participants
Region of Enrollment
Ireland
4 participants
n=164 Participants
4 participants
n=166 Participants
8 participants
n=330 Participants
Region of Enrollment
Spain
7 participants
n=164 Participants
8 participants
n=166 Participants
15 participants
n=330 Participants
Region of Enrollment
Sweden
2 participants
n=164 Participants
5 participants
n=166 Participants
7 participants
n=330 Participants
Region of Enrollment
Switzerland
6 participants
n=164 Participants
4 participants
n=166 Participants
10 participants
n=330 Participants
Region of Enrollment
United Kingdom
23 participants
n=164 Participants
17 participants
n=166 Participants
40 participants
n=330 Participants
Region of Enrollment
United States
20 participants
n=164 Participants
26 participants
n=166 Participants
46 participants
n=330 Participants
Geographic Region
North America
25 Participants
n=164 Participants
34 Participants
n=166 Participants
59 Participants
n=330 Participants
Geographic Region
Europe and Rest of World excluding Japan
129 Participants
n=164 Participants
121 Participants
n=166 Participants
250 Participants
n=330 Participants
Geographic Region
Japan
10 Participants
n=164 Participants
11 Participants
n=166 Participants
21 Participants
n=330 Participants
ANCA-associated vasculitis Status
Newly diagnosed
114 Participants
n=164 Participants
115 Participants
n=166 Participants
229 Participants
n=330 Participants
ANCA-associated vasculitis Status
Relapsed
50 Participants
n=164 Participants
51 Participants
n=166 Participants
101 Participants
n=330 Participants
ANCA Positivity
Proteinase 3 (PR3)
70 Participants
n=164 Participants
72 Participants
n=166 Participants
142 Participants
n=330 Participants
ANCA Positivity
Myeloperoxidase (MPO)
94 Participants
n=164 Participants
94 Participants
n=166 Participants
188 Participants
n=330 Participants
Standard of Care Treatment
Rituximab
107 Participants
n=164 Participants
107 Participants
n=166 Participants
214 Participants
n=330 Participants
Standard of Care Treatment
Intravenous (IV) Cyclophosphamide
51 Participants
n=164 Participants
51 Participants
n=166 Participants
102 Participants
n=330 Participants
Standard of Care Treatment
Oral Cyclophosphamide
6 Participants
n=164 Participants
8 Participants
n=166 Participants
14 Participants
n=330 Participants
Type of ANCA-associated vasculitis
Granulomatosis with polyangiitis (GPA)
90 Participants
n=164 Participants
91 Participants
n=166 Participants
181 Participants
n=330 Participants
Type of ANCA-associated vasculitis
Microscopic polyangiitis (MPA)
74 Participants
n=164 Participants
75 Participants
n=166 Participants
149 Participants
n=330 Participants
BVAS Entry Criteria
One or more major item
102 Participants
n=164 Participants
104 Participants
n=166 Participants
206 Participants
n=330 Participants
BVAS Entry Criteria
Three or more minor items
142 Participants
n=164 Participants
146 Participants
n=166 Participants
288 Participants
n=330 Participants
BVAS Entry Criteria
Two renal items of proteinuria and hematuria
57 Participants
n=164 Participants
60 Participants
n=166 Participants
117 Participants
n=330 Participants
BVAS Components
General
114 Participants
n=164 Participants
111 Participants
n=166 Participants
225 Participants
n=330 Participants
BVAS Components
Cutaneous
23 Participants
n=164 Participants
24 Participants
n=166 Participants
47 Participants
n=330 Participants
BVAS Components
Mucous Membranes/Eyes
40 Participants
n=164 Participants
26 Participants
n=166 Participants
66 Participants
n=330 Participants
BVAS Components
Ear Nose and Throat
69 Participants
n=164 Participants
75 Participants
n=166 Participants
144 Participants
n=330 Participants
BVAS Components
Chest
71 Participants
n=164 Participants
71 Participants
n=166 Participants
142 Participants
n=330 Participants
BVAS Components
Cardiovascular
3 Participants
n=164 Participants
6 Participants
n=166 Participants
9 Participants
n=330 Participants
BVAS Components
Abdominal
1 Participants
n=164 Participants
4 Participants
n=166 Participants
5 Participants
n=330 Participants
BVAS Components
Renal + Other (RBC Casts and/or Glomerulonephritis)
134 Participants
n=164 Participants
134 Participants
n=166 Participants
268 Participants
n=330 Participants
BVAS Components
Nervous System
31 Participants
n=164 Participants
38 Participants
n=166 Participants
69 Participants
n=330 Participants
Age at screening
60.5 years
STANDARD_DEVIATION 14.50 • n=164 Participants
61.2 years
STANDARD_DEVIATION 14.56 • n=166 Participants
60.9 years
STANDARD_DEVIATION 14.51 • n=330 Participants
Age at diagnosis of ANCA-associated Vasculitis
59.4 years
STANDARD_DEVIATION 15.19 • n=164 Participants
59.8 years
STANDARD_DEVIATION 15.60 • n=166 Participants
59.6 years
STANDARD_DEVIATION 15.37 • n=330 Participants
Duration of ANCA-Associated Vasculitis
20.13 months
STANDARD_DEVIATION 40.473 • n=164 Participants
22.93 months
STANDARD_DEVIATION 52.464 • n=166 Participants
21.54 months
STANDARD_DEVIATION 46.840 • n=330 Participants
Body Weight
77.71 kilogram(s)
STANDARD_DEVIATION 19.335 • n=164 Participants
76.43 kilogram(s)
STANDARD_DEVIATION 20.254 • n=166 Participants
77.07 kilogram(s)
STANDARD_DEVIATION 19.783 • n=330 Participants
BMI
26.78 kilogram(s)/square meter
STANDARD_DEVIATION 5.212 • n=163 Participants • Two subjects did not have a baseline BMI provided (one in each treatment group)
26.72 kilogram(s)/square meter
STANDARD_DEVIATION 5.997 • n=165 Participants • Two subjects did not have a baseline BMI provided (one in each treatment group)
26.75 kilogram(s)/square meter
STANDARD_DEVIATION 5.612 • n=328 Participants • Two subjects did not have a baseline BMI provided (one in each treatment group)
BVAS Score
16.2 units on a scale
STANDARD_DEVIATION 5.69 • n=164 Participants
16.3 units on a scale
STANDARD_DEVIATION 5.87 • n=166 Participants
16.2 units on a scale
STANDARD_DEVIATION 5.77 • n=330 Participants
VDI Score
0.7 units on a scale
STANDARD_DEVIATION 1.39 • n=163 Participants • Two subjects did not have a baseline VDI Score (one in each treatment group)
0.7 units on a scale
STANDARD_DEVIATION 1.54 • n=165 Participants • Two subjects did not have a baseline VDI Score (one in each treatment group)
0.7 units on a scale
STANDARD_DEVIATION 1.47 • n=328 Participants • Two subjects did not have a baseline VDI Score (one in each treatment group)

PRIMARY outcome

Timeframe: Week 26

Population: Intent-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

Disease remission at Week 26 was defined as: * Achieving a BVAS of 0 as determined by the Adjudication Committee; * No administration of glucocorticoids given for ANCA-associated vasculitis within 4 weeks prior to Week 26; * No BVAS \>0 during the 4 weeks prior to Week 26 (if collected for an unscheduled assessment).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Percentage of Subjects Achieving Disease Remission at Week 26
70.1 percentage of participants
Interval 62.5 to 77.0
72.3 percentage of participants
Interval 64.8 to 78.9

PRIMARY outcome

Timeframe: Week 52

Population: Intent-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

Sustained remission at Week 52 was defined as: * Disease remission at Week 26 as defined above; * Disease remission at Week 52 defined as a BVAS of 0 at Week 52 as determined by the Adjudication Committee and no administration of glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to Week 52; * No disease relapse between Week 26 and Week 52 as determined by the Adjudication Committee.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Percentage of Subjects Achieving Sustained Disease Remission at Week 52
54.9 percentage of participants
Interval 46.9 to 62.6
65.7 percentage of participants
Interval 57.9 to 72.8

SECONDARY outcome

Timeframe: From day 1 throughout the study period (day 421/week 60)

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug.

AEs=Adverse events SAEs=Serious adverse events TEAE=Treatment-emergent adverse event

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Subject Incidence of Treatment-emergent SAEs, AEs, and Withdrawals Due to AEs
Number of subjects with at least one TEAE
161 Number
164 Number
Subject Incidence of Treatment-emergent SAEs, AEs, and Withdrawals Due to AEs
Number of TEAEs
2139 Number
1779 Number
Subject Incidence of Treatment-emergent SAEs, AEs, and Withdrawals Due to AEs
Number of subjects with SAEs
74 Number
70 Number
Subject Incidence of Treatment-emergent SAEs, AEs, and Withdrawals Due to AEs
Number of SAEs
166 Number
116 Number
Subject Incidence of Treatment-emergent SAEs, AEs, and Withdrawals Due to AEs
Subjects with TEAE leading to discontinuation
28 Number
27 Number

SECONDARY outcome

Timeframe: Baseline, Week 13 and 26

Population: Intent-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug. The number of subjects with data at the specified visit is reported.

GTI-CWS=Glucocorticoid Toxicity Index Cumulative Worsening Score; GTI-AIS=Glucocorticoid Toxicity Index Aggregate Improvement Score; The Glucocorticoid Toxicity Index (GTI) was developed to score glucocorticoid toxicity. The GTI includes: the Cumulative Worsening Score (CWS) that captures cumulative toxicity, both permanent and transient, over the course of time (serves as a cumulative record of toxicity); and the Aggregate Improvement Score that captures both improvement and worsening of toxicity over time (serves as a record of both improving and worsening toxicity). Both scores range from 0 (best health) to 100 (worst health).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Glucocorticoid-induced Toxicity as Measured by Change From Baseline Over the First 26 Weeks in the GTI
GTI-CWS (Week 26)
56.6 Glucocorticoid Toxicity Index
Standard Error 3.45
39.7 Glucocorticoid Toxicity Index
Standard Error 3.43
Glucocorticoid-induced Toxicity as Measured by Change From Baseline Over the First 26 Weeks in the GTI
GTI-AIS (Week 13)
23.2 Glucocorticoid Toxicity Index
Standard Error 3.46
9.9 Glucocorticoid Toxicity Index
Standard Error 3.45
Glucocorticoid-induced Toxicity as Measured by Change From Baseline Over the First 26 Weeks in the GTI
GTI-AIS (Week 26)
23.4 Glucocorticoid Toxicity Index
Standard Error 3.50
11.2 Glucocorticoid Toxicity Index
Standard Error 3.48
Glucocorticoid-induced Toxicity as Measured by Change From Baseline Over the First 26 Weeks in the GTI
GTI-CWS (Week 13)
36.6 Glucocorticoid Toxicity Index
Standard Error 3.41
25.7 Glucocorticoid Toxicity Index
Standard Error 3.40

SECONDARY outcome

Timeframe: Week 4

Population: Intent-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

AC=Adjudication Committee; BVAS=Birmingham Vasculitis Activity Score; The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Percentage of Participants With BVAS of 0 at Week 4, Regardless of Whether the Subjects Received Glucocorticoids During This Period of Time and Based on Assessment by the Blinded AC
68.9 percentage of participants
Interval 61.2 to 75.9
62.7 percentage of participants
Interval 54.8 to 70.0

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Intent-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug. The number of subjects with data at the specified visit is reported.

SF-36v2: Measure of health- related quality of life (Medical Outcomes Survey Short Form-36 version 2) EQ-5D-5L: EuroQuality of Life-5 Domains-5 Levels The SF-36v2 component scores and the EQ-5D-5L VAS score range from 0 (worst health) to 100 (best health). The EQ-5D-5L Index Score ranges from 0 (worst health) to 1 (best health).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=150 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=154 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Vitality (Week 26)
6.42 Change from baseline
Standard Error 1.751
12.03 Change from baseline
Standard Error 1.727
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
EQ-5D-5L Index Score (Week 52)
-0.0038 Change from baseline
Standard Error 0.01471
0.0474 Change from baseline
Standard Error 0.01451
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Physical Component Score (Week 52)
2.626 Change from baseline
Standard Error 0.7505
4.980 Change from baseline
Standard Error 0.7435
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Physical Functioning (Week 26)
1.88 Change from baseline
Standard Error 1.787
7.31 Change from baseline
Standard Error 1.773
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Mental Component Score (Week 26)
3.271 Change from baseline
Standard Error 0.8403
4.849 Change from baseline
Standard Error 0.8273
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Mental Health (Week 26)
6.84 Change from baseline
Standard Error 1.331
8.29 Change from baseline
Standard Error 1.318
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Physical Component Score (Week 26)
1.344 Change from baseline
Standard Error 0.7432
4.445 Change from baseline
Standard Error 0.7332
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Physical Functioning (Week 52)
4.82 Change from baseline
Standard Error 1.809
9.55 Change from baseline
Standard Error 1.790
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Role Physical (Week 26)
7.52 Change from baseline
Standard Error 2.198
16.78 Change from baseline
Standard Error 2.173
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Role Physical (Week 52)
12.27 Change from baseline
Standard Error 2.228
17.12 Change from baseline
Standard Error 2.198
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Bodily Pain (Week 26)
9.82 Change from baseline
Standard Error 2.197
14.75 Change from baseline
Standard Error 2.164
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Bodily Pain (Week 52)
11.87 Change from baseline
Standard Error 2.220
16.12 Change from baseline
Standard Error 2.185
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: General Health Perception (Week 26)
-2.89 Change from baseline
Standard Error 1.428
3.12 Change from baseline
Standard Error 1.405
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: General Health Perception (Week 52)
-0.17 Change from baseline
Standard Error 1.442
5.84 Change from baseline
Standard Error 1.420
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Mental Component Score (Week 52)
4.694 Change from baseline
Standard Error 0.8491
6.394 Change from baseline
Standard Error 0.8406
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Mental Health (Week 52)
9.66 Change from baseline
Standard Error 1.347
10.89 Change from baseline
Standard Error 1.337
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Role Emotional (Week 26)
1.40 Change from baseline
Standard Error 2.183
7.32 Change from baseline
Standard Error 2.158
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Role Emotional (Week 52)
4.14 Change from baseline
Standard Error 2.212
9.38 Change from baseline
Standard Error 2.181
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Social Functioning (Week 26)
11.09 Change from baseline
Standard Error 2.037
14.50 Change from baseline
Standard Error 2.002
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Social Functioning (Week 52)
13.56 Change from baseline
Standard Error 2.059
18.06 Change from baseline
Standard Error 2.030
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
SF-36v2: Vitality (Week 52)
10.48 Change from baseline
Standard Error 1.770
14.36 Change from baseline
Standard Error 1.750
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
EQ-5D-5L VAS Score (Week 26)
5.5 Change from baseline
Standard Error 1.39
9.1 Change from baseline
Standard Error 1.38
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
EQ-5D-5L VAS Score (Week 52)
7.1 Change from baseline
Standard Error 1.41
13.0 Change from baseline
Standard Error 1.39
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
EQ-5D-5L Index Score (Week 26)
-0.0010 Change from baseline
Standard Error 0.01462
0.0229 Change from baseline
Standard Error 0.01438

SECONDARY outcome

Timeframe: Week 52

Population: Intent-to-Treat (ITT) Subjects in the analysis population for the specified treatment group. ITT Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

The median time to relapse was not estimable because of small number of relapsed subjects. A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after: 1. having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or 2. having achieved BVAS=0 at any time during the treatment period ANCA=anti-neutrophil cytoplasmic autoantibody; BVAS=Birmingham Vasculitis Activity Score; The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=115 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=120 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving Remission at Week 26 in the Study
12.2 percentage of participants
Interval 6.8 to 19.6
7.5 percentage of participants
Interval 3.5 to 13.8

SECONDARY outcome

Timeframe: Week 52

Population: Intent-to-Treat (ITT) Subjects who achieved BVAS=0 during the 52 week treatment period. ITT Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

The median time to relapse was not estimable because of small number of relapsed subjects. A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after: 1. having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or 2. having achieved BVAS=0 at any time during the treatment period The Birmingham Vasculitis Activity Score (BVAS) form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=157 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=158 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving BVAS=0 at Any Time During the Treatment Period
21.0 percentage of participants
Interval 14.9 to 28.2
10.1 percentage of participants
Interval 5.9 to 15.9

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Intent-to-Treat (ITT) Subjects With Renal Disease at Baseline (based on BVAS). ITT Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

Change from baseline in kidney function, as measured by eGFR (based on the MDRD equation), was measured in subjects with renal disease based on the BVAS renal component. eGFR=estimated glomerular filtration rate BVAS=Birmingham Vasculitis Activity Score MDRD=Modification of Diet in Renal Disease

Outcome measures

Outcome measures
Measure
Prednisone Group
n=127 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=121 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Change in eGFR From Baseline Over 52 Weeks
Week 26
2.9 Change in eGFR (mL/min/1.73 m^2)
Interval 0.9 to 4.9
5.8 Change in eGFR (mL/min/1.73 m^2)
Interval 3.7 to 7.8
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Change in eGFR From Baseline Over 52 Weeks
Week 52
4.1 Change in eGFR (mL/min/1.73 m^2)
Interval 2.1 to 6.1
7.3 Change in eGFR (mL/min/1.73 m^2)
Interval 5.2 to 9.4

SECONDARY outcome

Timeframe: Baseline, Week 4, 26 and 52

Population: Intent-to-Treat (ITT) Subjects With Renal Disease (based on BVAS) and Albuminuria (UACR\>=10 mg/g creatinine) at Baseline ITT Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

BVAS=Birmingham Vasculitis Activity Score UACR=Urinary albumin:creatinine ratio

Outcome measures

Outcome measures
Measure
Prednisone Group
n=124 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=121 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
In Subjects With Renal Disease and Albuminuria at Baseline (Based in the BVAS Renal Component), the Percent Change in UACR From Baseline Over 52 Weeks
Week 4
0 Percentage change
Interval -16.0 to 19.0
-40 Percentage change
Interval -50.0 to -28.0
In Subjects With Renal Disease and Albuminuria at Baseline (Based in the BVAS Renal Component), the Percent Change in UACR From Baseline Over 52 Weeks
Week 26
-70 Percentage change
Interval -75.0 to -65.0
-63 Percentage change
Interval -69.0 to -56.0
In Subjects With Renal Disease and Albuminuria at Baseline (Based in the BVAS Renal Component), the Percent Change in UACR From Baseline Over 52 Weeks
Week 52
-77 Percentage change
Interval -81.0 to -72.0
-74 Percentage change
Interval -78.0 to -69.0

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Intent-to-Treat (ITT) Subjects With Renal Disease at Baseline (based on BVAS). ITT Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

BVAS=Birmingham Vasculitis Activity Score MCP-1=monocyte chemoattractant protein-1

Outcome measures

Outcome measures
Measure
Prednisone Group
n=117 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=106 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Percent Change in Urinary MCP-1:Creatinine Ratio From Baseline Over 52 Weeks
Week 26
-64 Percentage change
Interval -67.0 to -59.0
-67 Percentage change
Interval -70.0 to -63.0
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Percent Change in Urinary MCP-1:Creatinine Ratio From Baseline Over 52 Weeks
Week 52
-71 Percentage change
Interval -74.0 to -67.0
-73 Percentage change
Interval -76.0 to -70.0

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Intent-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug. The number of subjects with data at baseline and the specified visit is reported.

VDI=Vasculitis Damage Index; The VDI is comprised of 64 items of damage, grouped into 11 organ-based systems or categorizations. Damage is defined as the presence of non-healing scars and does not give any indication of current disease activity. Damage is also defined as having been present or currently present for at least 3 months. Completion of the form provides a numerical score, which ranges from 0 (best health) to 64 (worst health).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=155 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=161 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change in the VDI From Baseline Over 52 Weeks, Including the Week 26 and Week 52 Time Points
Week 52
1.15 score on a scale
Standard Error 0.093
1.17 score on a scale
Standard Error 0.091
Change in the VDI From Baseline Over 52 Weeks, Including the Week 26 and Week 52 Time Points
Week 26
0.97 score on a scale
Standard Error 0.092
1.06 score on a scale
Standard Error 0.090

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=151 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=147 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5)
Leukocytes (Week 26)
-5.69 10^3 cells/μL
Standard Error 0.338
-5.94 10^3 cells/μL
Standard Error 0.387
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5)
Leukocytes (Week 52)
-5.54 10^3 cells/μL
Standard Error 0.365
-5.62 10^3 cells/μL
Standard Error 0.395
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5)
Neutrophils (Week 26)
-5.10 10^3 cells/μL
Standard Error 0.338
-5.24 10^3 cells/μL
Standard Error 0.380
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5)
Neutrophils (Week 52)
-4.89 10^3 cells/μL
Standard Error 0.361
-4.95 10^3 cells/μL
Standard Error 0.372
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5)
Lymphocytes (Week 26)
-0.62 10^3 cells/μL
Standard Error 0.090
-0.84 10^3 cells/μL
Standard Error 0.099
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5)
Lymphocytes (Week 52)
-0.67 10^3 cells/μL
Standard Error 0.090
-0.82 10^3 cells/μL
Standard Error 0.100

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=152 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=147 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Monocytes (Week 26)
0.01 10^9 cells/L
Standard Error 0.022
-0.04 10^9 cells/L
Standard Error 0.024
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Monocytes (Week 52)
0.01 10^9 cells/L
Standard Error 0.024
-0.01 10^9 cells/L
Standard Error 0.026
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Platelets (Week 26)
-73.9 10^9 cells/L
Standard Error 8.49
-77.1 10^9 cells/L
Standard Error 9.30
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Platelets (Week 52)
-75.5 10^9 cells/L
Standard Error 8.01
-73.8 10^9 cells/L
Standard Error 9.31
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Eosinophils (Week 26)
0.07 10^9 cells/L
Standard Error 0.016
0.07 10^9 cells/L
Standard Error 0.018
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Eosinophils (Week 52)
0.05 10^9 cells/L
Standard Error 0.013
0.07 10^9 cells/L
Standard Error 0.019
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Basophils (Week 26)
-0.01 10^9 cells/L
Standard Error 0.004
-0.00 10^9 cells/L
Standard Error 0.004
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
Basophils (Week 52)
-0.01 10^9 cells/L
Standard Error 0.004
-0.01 10^9 cells/L
Standard Error 0.004

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=152 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=147 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (3/5)
Erythrocytes (Week 26)
0.226 10^12 cells/L
Standard Error 0.0450
0.252 10^12 cells/L
Standard Error 0.0432
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (3/5)
Erythrocytes (Week 52)
0.244 10^12 cells/L
Standard Error 0.0410
0.279 10^12 cells/L
Standard Error 0.0432

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=152 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=147 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (4/5)
Hemoglobin (Week 26)
1.07 g/dL
Standard Error 0.129
1.10 g/dL
Standard Error 0.120
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (4/5)
Hemoglobin (Week 52)
1.20 g/dL
Standard Error 0.126
1.27 g/dL
Standard Error 0.125

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=152 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=147 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (5/5)
Hematocrit (Week 52)
3.0 percentage of red blood cells
Standard Error 0.37
3.2 percentage of red blood cells
Standard Error 0.38
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (5/5)
Hematocrit (Week 26)
2.6 percentage of red blood cells
Standard Error 0.38
2.7 percentage of red blood cells
Standard Error 0.38

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=154 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=150 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Lactate Dehydrogenase (Week 26)
2.3 U/L
Standard Error 5.68
-6.1 U/L
Standard Error 5.40
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Lactate Dehydrogenase (Week 52)
-8.6 U/L
Standard Error 5.33
-10.7 U/L
Standard Error 4.80
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Alanine Aminotransferase (Week 26)
-6.8 U/L
Standard Error 1.77
-6.1 U/L
Standard Error 1.54
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Alanine Aminotransferase (Week 52)
-8.2 U/L
Standard Error 1.57
-7.2 U/L
Standard Error 1.46
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Aspartate Aminotransferase (Week 26)
1.9 U/L
Standard Error 0.98
2.5 U/L
Standard Error 0.72
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Alkaline Phosphatase (Week 26)
-0.6 U/L
Standard Error 2.47
-3.9 U/L
Standard Error 2.84
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Alkaline Phosphatase (Week 52)
0.8 U/L
Standard Error 1.77
-4.0 U/L
Standard Error 2.34
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Creatine Kinase (Week 26)
47.6 U/L
Standard Error 5.27
76.8 U/L
Standard Error 10.34
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Creatine Kinase (Week 52)
57.6 U/L
Standard Error 5.67
76.3 U/L
Standard Error 9.68
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
Aspartate Aminotransferase (Week 52)
0.5 U/L
Standard Error 0.85
2.0 U/L
Standard Error 0.69

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=159 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=162 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Urea Nitrogen (Week 52)
-7.8 mg/dL
Standard Error 1.11
-11.9 mg/dL
Standard Error 1.32
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Protein (Week 26)
50 mg/dL
Standard Error 50
220 mg/dL
Standard Error 47
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Protein (Week 52)
160 mg/dL
Standard Error 48
250 mg/dL
Standard Error 41
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Creatinine (Week 26)
-0.105 mg/dL
Standard Error 0.0569
-0.195 mg/dL
Standard Error 0.0508
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Creatinine (Week 52)
-0.200 mg/dL
Standard Error 0.0416
-0.244 mg/dL
Standard Error 0.0627
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Urea Nitrogen (Week 26)
-9.4 mg/dL
Standard Error 1.16
-11.0 mg/dL
Standard Error 1.32
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Cholesterol (Week 26)
19.0 mg/dL
Standard Error 4.27
7.4 mg/dL
Standard Error 3.99
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Cholesterol (Week 52)
13.8 mg/dL
Standard Error 4.28
9.3 mg/dL
Standard Error 4.05
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
LDL Cholesterol (Week 26)
22.7 mg/dL
Standard Error 3.66
12.0 mg/dL
Standard Error 3.47
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
LDL Cholesterol (Week 52)
21.7 mg/dL
Standard Error 3.48
11.9 mg/dL
Standard Error 3.41
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Bilirubin (Week 26)
0.065 mg/dL
Standard Error 0.0182
0.078 mg/dL
Standard Error 0.0250
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
Bilirubin (Week 52)
0.053 mg/dL
Standard Error 0.0185
0.057 mg/dL
Standard Error 0.0201

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=154 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=154 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline in Vital Signs (1/5)
Systolic Blood Pressure (Week 26)
-2.5 mmHg
Standard Error 1.70
-2.6 mmHg
Standard Error 1.54
Change From Baseline in Vital Signs (1/5)
Systolic Blood Pressure (Week 52)
-2.4 mmHg
Standard Error 1.64
-1.0 mmHg
Standard Error 1.60
Change From Baseline in Vital Signs (1/5)
Diastolic Blood Pressure (Week 26)
2.7 mmHg
Standard Error 0.98
0.5 mmHg
Standard Error 0.92
Change From Baseline in Vital Signs (1/5)
Diastolic Blood Pressure (Week 52)
1.4 mmHg
Standard Error 1.01
1.4 mmHg
Standard Error 1.00

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=152 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=154 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline in Vital Signs (2/5)
Pulse Rate (Week 26)
2.2 beats/min
Standard Error 1.12
0.9 beats/min
Standard Error 1.25
Change From Baseline in Vital Signs (2/5)
Pulse Rate (Week 52)
-1.3 beats/min
Standard Error 1.07
-0.3 beats/min
Standard Error 1.21

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=152 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=151 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline in Vital Signs (3/5)
Temperature (Week 52)
0.04 degree Celsius
Standard Error 0.044
-0.11 degree Celsius
Standard Error 0.048
Change From Baseline in Vital Signs (3/5)
Temperature (Week 26)
-0.03 degree Celsius
Standard Error 0.043
-0.11 degree Celsius
Standard Error 0.046

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

Outcome measures

Outcome measures
Measure
Prednisone Group
n=154 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=153 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline in Vital Signs (4/5)
Weight (Week 26)
3.33 kilogram(s)
Standard Error 0.397
1.93 kilogram(s)
Standard Error 0.369
Change From Baseline in Vital Signs (4/5)
Weight (Week 52)
3.27 kilogram(s)
Standard Error 0.477
2.59 kilogram(s)
Standard Error 0.487

SECONDARY outcome

Timeframe: Baseline, Week 26 and 52

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug. The number of subjects with data at baseline and the specified visit is reported.

BMI=Body Mass Index

Outcome measures

Outcome measures
Measure
Prednisone Group
n=153 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=152 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Change From Baseline in Vital Signs (5/5)
BMI (Week 26)
1.13 kilogram(s)/ square meter
Standard Error 0.135
0.67 kilogram(s)/ square meter
Standard Error 0.132
Change From Baseline in Vital Signs (5/5)
BMI (Week 52)
1.12 kilogram(s)/ square meter
Standard Error 0.164
0.94 kilogram(s)/ square meter
Standard Error 0.179

SECONDARY outcome

Timeframe: From day 1 throughout the study period (day 421/week 60)

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug.

Clinical significance was assessed by the individual reading of the ECGs ECG=Electrocardiogram

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Number of Subjects With Clinically Significant ECG Changes From Baseline
8 Participants
12 Participants

SECONDARY outcome

Timeframe: From day 1 throughout the study period (day 421/week 60)

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug.

AE=Adverse Event

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
Relationship of glucocorticoid use to an AE
131 Participants
107 Participants
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
Relationship of cyclophosphamide IV use to an AE
30 Participants
31 Participants
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
Relationship of oral cyclophosphamide use to an AE
4 Participants
8 Participants
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
Relationship of rituximab use to an AE
61 Participants
50 Participants
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
Relationship of azathioprine use to an AE
35 Participants
28 Participants
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
Relationship of mycophenolate use to an AE
9 Participants
6 Participants
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
Relationship of avacopan/placebo to an AE
103 Participants
100 Participants

SECONDARY outcome

Timeframe: From day 1 throughout the study period (day 421/week 60)

Population: Safety Population: The safety population included all subjects who were randomized and had received at least one dose of study drug.

WBC=White Blood Cell TEAE=Treatment-Emergent Adverse Event

Outcome measures

Outcome measures
Measure
Prednisone Group
n=164 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=166 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any Treatment-Emergent Infection
124 Participants
113 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any Serious Treatment-Emergent Infection
25 Participants
22 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any Treatment-Emergent Infection Leading to Study Withdrawal
5 Participants
4 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any Treatment-Emergent Life-threatening Infection
2 Participants
1 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any TEAE Associated with Low WBC Counts
39 Participants
31 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any Severe Treatment-Emergent Infection
10 Participants
12 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any Treatment-Emergent Infection Leading to Death
2 Participants
1 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any TEAE Associated with Hepatic Abnormalities
19 Participants
22 Participants
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
Any TEAE Associated with hypersensitivity
70 Participants
68 Participants

SECONDARY outcome

Timeframe: From day 1 throughout the study period (day 421/week 60)

Population: Intended-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.

BVAS=Birmingham Vasculitis Activity Score; A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after: 1. having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or 2. having achieved BVAS=0 at any time during the treatment period The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).

Outcome measures

Outcome measures
Measure
Prednisone Group
n=157 Participants
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Avacopan Group
n=158 Participants
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study
33 Participants
16 Participants

Adverse Events

Prednisone Group

Serious events: 74 serious events
Other events: 161 other events
Deaths: 4 deaths

Avacopan Group

Serious events: 70 serious events
Other events: 164 other events
Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure
Prednisone Group
n=164 participants at risk
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone. The safety population included all subjects who were randomized and had received at least one dose of study drug.
Avacopan Group
n=166 participants at risk
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo. The safety population included all subjects who were randomized and had received at least one dose of study drug.
Nervous system disorders
Hypoaesthesia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Hypokalaemia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Vascular disorders
Granulomatosis with polyangiitis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
3.0%
5/166 • Number of events 5 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Vascular disorders
Microscopic polyangiitis
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Immune system disorders
Drug hypersensitivity
1.2%
2/164 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Pyrexia
1.8%
3/164 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Immune system disorders
Anti-neutrophil cytoplasmic antibody positive vasculitis
12.2%
20/164 • Number of events 25 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
7.2%
12/166 • Number of events 12 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Hepatic enzyme increased
1.8%
3/164 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Blood creatinine increased
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Cardiac disorders
Angina pectoris
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Cardiac disorders
Cardiac failure
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Cardiac disorders
Acute myocardial infarction
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Pulmonary alveolar haemorrhage
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Epistaxis
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
1.8%
3/164 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Agranulocytosis
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Lymphopenia
1.8%
3/164 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Anaemia
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Neutropenia
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Thrombocytopenia
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Mononeuropathy multiplex
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Diarrhoea
1.8%
3/164 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Large intestine polyp
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Vomiting
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Hepatobiliary disorders
Hepatic function abnormal
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Renal and urinary disorders
Acute kidney injury
0.61%
1/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.8%
3/166 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Renal and urinary disorders
Glomerulonephritis
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Hyperglycaemia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Dehydration
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Pneumonia
3.7%
6/164 • Number of events 6 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
4.8%
8/166 • Number of events 9 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Urinary tract infection
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.8%
3/166 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Device related infection
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Influenza
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Herpes zoster
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Infectious pleural effusion
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Pneumonia bacterial
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Respiratory syncytial virus infection
1.2%
2/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Abdominal hernia
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Abdominal pain upper
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Skin and subcutaneous tissue disorders
Angioedema
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Antineutrophil cytoplasmic antibody increased
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Surgical and medical procedures
Arteriovenous fistula operation
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Arthralgia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Aspartate aminotransferase increased
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Asthma
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Cardiac disorders
Atrioventricular block first degree
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Bronchitis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Bronchopneumopathy
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Campylobacter gastroenteritis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Hepatobiliary disorders
Cholelithiasis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Diabetic ketoacidosis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Hepatobiliary disorders
Drug-induced liver injury
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Renal and urinary disorders
End stage renal disease
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Facial paralysis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Febrile neutropenia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Gastrointestinal haemorrhage
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Gout
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Renal and urinary disorders
Haematuria
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Hepatobiliary disorders
Hepatitis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Hepatitis B
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Hepatobiliary disorders
Hepatitis cholestatic
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Hepatobiliary disorders
Hepatocellular injury
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Hip fracture
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Humerus fracture
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Vascular disorders
Hypertension
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Hypoglycaemia
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Infusion related reaction
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Inguinal hernia
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Intestinal obstruction
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Liver function test increased
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Multiple fractures
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Nausea
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Neutropenic sepsis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Oedema
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Oedema peripheral
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Orthopnoea
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Osteonecrosis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Pancreatitis acute
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Pneumonia haemophilus
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Post procedural sepsis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Procedural pain
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Procedural vomiting
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Pulmonary haemorrhage
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Renal and urinary disorders
Renal impairment
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Sepsis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Skin and subcutaneous tissue disorders
Skin necrosis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Cardiac disorders
Tachycardia
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Vascular disorders
Thrombosis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Urosepsis
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Vasculitis gastrointestinal
0.00%
0/164 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Abdominal pain
0.61%
1/164 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Endocrine disorders
Adrenal insufficiency
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Alanine aminotransferase increased
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Psychiatric disorders
Anxiety
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Aspergillus infection
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Asthenia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Bacteraemia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Reproductive system and breast disorders
Benign prostatic hyperplasia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Bone marrow failure
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Bone marrow toxicity
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of skin
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Cerebral infarction
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Chondrocalcinosis pyrophosphate
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Renal and urinary disorders
Chronic kidney disease
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Cardiac disorders
Coronary artery disease
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Cryptococcosis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Death
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Vascular disorders
Deep vein thrombosis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Psychiatric disorders
Depression
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Product Issues
Device malfunction
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Duodenitis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Enterocolitis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Eye disorders
Episcleritis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Fungal infection
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Gastrointestinal disorder
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Granulomatous lymphadenitis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Hernia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Hyperkalaemia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Laryngeal stenosis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Lower respiratory tract infection
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Lumbar vertebral fracture
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Lymphocyte count decreased
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Psychiatric disorders
Major depression
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Medical observation
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Meningitis
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Myalgia
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Cardiac disorders
Myocardial infarction
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Nasal ulcer
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Nervous system disorder
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Non-cardiac chest pain
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Ophthalmic herpes simplex
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Parainfluenzae virus infection
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Pharyngeal ulceration
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Pneumomediastinum
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Pneumonia cytomegaloviral
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Injury, poisoning and procedural complications
Post procedural haematoma
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Pulmonary arterial hypertension
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Skin and subcutaneous tissue disorders
Purpura
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Rectal prolapse
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Respiratory tract infection viral
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Small intestinal haemorrhage
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Psychiatric disorders
Somatic symptom disorder
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Staphylococcal infection
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Subcutaneous abscess
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Systemic inflammatory response syndrome
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Transaminases increased
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
0.61%
1/164 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.00%
0/166 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.

Other adverse events

Other adverse events
Measure
Prednisone Group
n=164 participants at risk
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone. The safety population included all subjects who were randomized and had received at least one dose of study drug.
Avacopan Group
n=166 participants at risk
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo. The safety population included all subjects who were randomized and had received at least one dose of study drug.
Vascular disorders
Hypertension
17.7%
29/164 • Number of events 31 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
18.1%
30/166 • Number of events 36 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Immune system disorders
Anti-neutrophil cytoplasmic antibody positive vasculitis
20.7%
34/164 • Number of events 46 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
15.7%
26/166 • Number of events 30 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Oedema peripheral
24.4%
40/164 • Number of events 56 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
21.1%
35/166 • Number of events 39 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Fatigue
9.1%
15/164 • Number of events 15 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
10.2%
17/166 • Number of events 19 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
General disorders
Pyrexia
11.6%
19/164 • Number of events 25 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
9.0%
15/166 • Number of events 18 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Psychiatric disorders
Insomnia
15.2%
25/164 • Number of events 27 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
7.8%
13/166 • Number of events 13 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Weight increased
10.4%
17/164 • Number of events 19 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
0.60%
1/166 • Number of events 1 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Investigations
Blood creatinine increased
4.9%
8/164 • Number of events 10 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
6.0%
10/166 • Number of events 10 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Cough
15.9%
26/164 • Number of events 29 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
15.7%
26/166 • Number of events 31 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Epistaxis
12.8%
21/164 • Number of events 30 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
8.4%
14/166 • Number of events 21 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
6.7%
11/164 • Number of events 14 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
4.8%
8/166 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
7.3%
12/164 • Number of events 12 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
3.6%
6/166 • Number of events 7 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Anaemia
11.0%
18/164 • Number of events 19 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
7.8%
13/166 • Number of events 13 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Leukopenia
8.5%
14/164 • Number of events 20 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
7.2%
12/166 • Number of events 15 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Increased tendency to bruise
6.1%
10/164 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
4.2%
7/166 • Number of events 7 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Blood and lymphatic system disorders
Lymphopenia
11.0%
18/164 • Number of events 27 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
3.6%
6/166 • Number of events 7 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Headache
14.0%
23/164 • Number of events 30 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
20.5%
34/166 • Number of events 43 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Dizziness
6.1%
10/164 • Number of events 10 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
6.6%
11/166 • Number of events 14 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Tremor
6.1%
10/164 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.2%
2/166 • Number of events 2 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Nervous system disorders
Paraesthesia
4.3%
7/164 • Number of events 8 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
5.4%
9/166 • Number of events 10 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Nausea
20.7%
34/164 • Number of events 46 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
23.5%
39/166 • Number of events 54 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Diarrhoea
14.6%
24/164 • Number of events 31 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
15.1%
25/166 • Number of events 33 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Vomiting
12.8%
21/164 • Number of events 27 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
15.1%
25/166 • Number of events 29 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Abdominal pain upper
6.1%
10/164 • Number of events 13 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
6.6%
11/166 • Number of events 12 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Constipation
6.7%
11/164 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
6.6%
11/166 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Dyspepsia
6.1%
10/164 • Number of events 12 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
3.0%
5/166 • Number of events 6 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Rash
7.9%
13/164 • Number of events 17 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
11.4%
19/166 • Number of events 26 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Pruritus
6.1%
10/164 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
6.0%
10/166 • Number of events 15 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Gastrointestinal disorders
Alopecia
7.3%
12/164 • Number of events 12 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
4.2%
7/166 • Number of events 7 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Arthralgia
22.0%
36/164 • Number of events 48 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
18.7%
31/166 • Number of events 42 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Muscle spasms
22.6%
37/164 • Number of events 47 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
10.8%
18/166 • Number of events 23 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Back pain
13.4%
22/164 • Number of events 22 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
9.6%
16/166 • Number of events 16 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Myalgia
13.4%
22/164 • Number of events 25 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
9.6%
16/166 • Number of events 17 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Musculoskeletal and connective tissue disorders
Pain in extremity
7.9%
13/164 • Number of events 13 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
7.8%
13/166 • Number of events 13 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Endocrine disorders
Cushingoid
5.5%
9/164 • Number of events 9 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
1.8%
3/166 • Number of events 3 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Metabolism and nutrition disorders
Hypercholesterolaemia
12.2%
20/164 • Number of events 21 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
7.2%
12/166 • Number of events 13 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Nasopharyngitis
18.3%
30/164 • Number of events 46 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
15.1%
25/166 • Number of events 38 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Upper respiratory tract infection
14.6%
24/164 • Number of events 33 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
14.5%
24/166 • Number of events 28 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Urinary tract infection
14.0%
23/164 • Number of events 33 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
7.2%
12/166 • Number of events 19 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Pneumonia
6.7%
11/164 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
6.6%
11/166 • Number of events 12 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Sinusitis
7.3%
12/164 • Number of events 12 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
6.0%
10/166 • Number of events 10 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
Infections and infestations
Bronchitis
6.1%
10/164 • Number of events 11 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.
3.0%
5/166 • Number of events 7 • From day 1 throughout the study period (day 421/week 60)
An AE was considered treatment-emergent if the start date/time of the event was on or after the date/time of first dose of study drug through 56 days following the last dose administered during the randomized treatment period.

Additional Information

Clinical trial disclosure

ChemoCentryx, Inc.

Phone: 650.210.2900

Results disclosure agreements

  • Principal investigator is a sponsor employee The PI shall provide Sponsor with an advance copy of any proposed publication or oral presentation at least 60 days prior to the planned date of submission or presentation and Sponsor shall have 60 days to review the proposed publication. Sponsor may request in writing, and the PI shall agree to, (a) the deletion of any Confidential Information, (b) any reasonable changes requested by Sponsor, or (c) a delay of such proposed submission for an additional period, not to exceed 90 days.
  • Publication restrictions are in place

Restriction type: OTHER